Area of research
Oncology · Immunology
Research interest
Research focused on Cytokine release syndrome and Immunology, with related work in Biomarker, MAGIC (telescope), Neuroinflammation. Notable publications include 'The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease', 'Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation', and 'Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant'.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature
Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation